Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.91 USD | -2.55% | -1.55% | -28.46% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 2.58M |
---|---|---|---|---|---|
Net income 2024 * | -23M | Net income 2025 * | -26M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.15
x | P/E ratio 2025 * |
-0.08
x | Employees | 12 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.68% |
Latest transcript on Cyclacel Pharmaceuticals, Inc.
1 day | +17.37% | ||
1 week | -4.39% | ||
Current month | -7.10% | ||
1 month | -19.34% | ||
3 months | -6.22% | ||
6 months | -80.55% | ||
Current year | -26.59% |
Managers | Title | Age | Since |
---|---|---|---|
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 97-07-31 |
Paul McBarron
DFI | Director of Finance/CFO | 63 | 01-12-31 |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 20-12-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 83 | 06-02-28 | |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 20-12-16 |
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 97-07-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 1.91 | -2.55% | 33 095 |
24-04-17 | 1.96 | +17.37% | 115,080 |
24-04-16 | 1.67 | +6.37% | 48,891 |
24-04-15 | 1.57 | -10.80% | 38,778 |
24-04-12 | 1.76 | -9.28% | 29,512 |
Delayed Quote Nasdaq, April 17, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.59% | 2.58M | |
-3.39% | 102B | |
+2.61% | 96.84B | |
-0.84% | 21.48B | |
-18.14% | 20.82B | |
-7.22% | 18.6B | |
-40.70% | 16.81B | |
-26.89% | 13.78B | |
+1.12% | 13.4B | |
+22.25% | 11.06B |
- Stock Market
- Equities
- CYCC Stock